The US Food and Drug Administration has approved a new treatment option for Tarceva (erlotinib) for patients with locally advanced or metastatic non-small cell lung cancer. This follows a positive opinion for the same indication from the EMA. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
